Trading

Data

Solutions

Insights

Pulmonx Stock

pulmonx.comHealthcareFunding to Date: $226.39MM

Pulmonx is the developer of the Zephyr Endobronchial Valve, a minimally invasive treatment for COPD/emphysema.

Learn more about Pulmonx IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for Pulmonx.

Register Today

Team

Management Team

Martin Schneider

Chief Financial Officer, Pulmonx International SARL & Vice President, Finance & Administration

Glendon French

Chief Executive Officer, President & Board Member

Rodney Perkins MD

Founder & Chairman of the Board

Board Members

Charles Chon

Oern Stuge MD

HealthCap

Rodney Perkins MD

Stephen Salmon

Dana Mead Jr.

Kleiner Perkins

Richard Ferrari

De Novo Ventures

Staffan Lindstrand

HealthCap

Glendon French

Michael Matly MD

Montreux Growth Partners

Annette Campbell-White

MedVenture Associates

Other companies like Pulmonx in the Healthcare sector

Altos Labs

Sector

Healthcare

Last Round Est. Valuation

$3.67B

Acelyrin

Sector

Healthcare

Last Round Est. Valuation

$809.52MM

Colossal Biosciences

Sector

Healthcare

Last Round Est. Valuation

$1.01B

Sector

Sector

Last Round Est. Valuation

$4.26B

Sector

Sector

Last Round Est. Valuation

$396.01MM

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Alzheon

Sector

Healthcare

Last Round Est. Valuation

$1.53B

News

Business Wire 05/09/2019

Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer

Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65

Popular Topics

Popular Topics

Pulmonx Stock

Register for Details